%0 Journal Article %A Ethan Romero-Severson %A Nick Hengartner %A Grant David Meadors %A Ruian Ke %T Decline in global transmission rates of COVID-19 through May 6 2020 %D 2020 %R 10.1101/2020.04.18.20070771 %J medRxiv %P 2020.04.18.20070771 %X We analyzed COVID-19 data through May 6th, 2020 using a partially observed Markov process. Our method uses a hybrid deterministic and stochastic formalism that allows for time variable transmission rates and detection probabilities. The model was fit using iterated particle filtering to case count and death count time series from 55 countries. We found evidence for a shrinking epidemic in 30 of the 55 examined countries. Of those 30 countries, 27 have significant evidence for subcritical transmission rates, although the decline in new cases is relatively slow compared to the initial growth rates. Generally, the transmission rates in Europe were lower than in the Americas and Asia. This suggests that global scale social distancing efforts to slow the spread of COVID-19 are effective although they need to be strengthened in many regions and maintained in others to avoid further resurgence of COVID-19. The slow decline also suggests alternative strategies to control the virus are needed before social distancing efforts are partially relaxed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors were funded by Laboratory Directed Research and Development grant 20200002CR.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the manuscript are publicly available at https://github.com/CSSEGISandData/COVID-19 https://github.com/CSSEGISandData/COVID-19 %U https://www.medrxiv.org/content/medrxiv/early/2020/05/22/2020.04.18.20070771.full.pdf